Drugs / Baicalein
Baicalein
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03830684 | Feb → May 2019 | influenza | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Baicalein | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03830684 ↗ |
| Known as | Noroxylin | ChEMBL registry synonym — accepted as the source's own label CHEMBL8260 ↗ |
| Known as | NSC-661431 | ChEMBL registry synonym — accepted as the source's own label CHEMBL8260 ↗ |
| Action | Inhibit | “both attenuated by 12/15-LOX siRNA or the specific inhibitor baicalein and ML351” PMID 41313942 ↗ Nov 2025 |
| Modality | Small molecule | — CHEMBL8260 ↗ |